Intestinal fibrosis is a challenge to management of patients with Crohn’s disease (CD); there is an urgent need to expedite development of anti-fibrosis drugs for this disease. The International Organization for the Study of Inflammatory Bowel Disease (IOIBD) aimed to identify a set of endpoints that can be used to determine efficacy of anti-fibrosis agents tested in clinical trials of patients with CD.